File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator

TitleEffect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator
Authors
Tse, HFWang, QYu, CMAyers, GMLau, CP
KeywordsAtrial fibrillation
Verapamil
Issue Date2001
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.clinicalcardiology.org
Citation
Clinical Cardiology, 2001, v. 24 n. 7, p. 503-505 How to Cite?
DOI: http://dx.doi.org/10.1002/clc.4960240717
AbstractBackground: The role of verapamil in the prevention of atrial fibrillation (AF) in patients with recurrent AF is unknown. Hypothesis: The aim of this study was to evaluate the effect of verapamil on the prevention of AF in patients implanted with an implantable atrial defibrillator (IAD). Methods: The effects of verapamil (240 mg/day) on the total duration of AF, number of AF recurrences, and number of cardioversions were prospectively evaluated in a randomized, crossover fashion over an 8-week period in 11 patients (9 men, 2 women; mean age: 60 ± 6 years) implanted with an IAD. Results: Implantable atrial defibrillators successfully converted 13 of 14 (93%) spontaneous episodes of AF. There was no significant difference in the efficacy of cardioversion (86 vs. 100%, p = 0.8), the total duration of AF (173 ± 198 vs. 270 ± 241 h, p = 0.5), the number of AF episodes (8.5 ± 9.0 vs. 9.3 ± 10.2, p = 0.3), and the number of cardioversions (1.7 ± 2.4 vs. 1.8 ± 2.1, p = 0.7) with or without treatment with verapamil. Conclusions: The results of the present study suggest that treatment with verapamil has no significant effect on the prevention of AF in patients treated with an IAD.
Persistent Identifierhttp://hdl.handle.net/10722/77177
ISSN
0160-9289
2021 Impact Factor: 3.287
2020 SCImago Journal Rankings: 1.263
ISI Accession Number ID
WOS:000169516900004
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorTse, HFen_HK
dc.contributor.authorWang, Qen_HK
dc.contributor.authorYu, CMen_HK
dc.contributor.authorAyers, GMen_HK
dc.contributor.authorLau, CPen_HK
dc.date.accessioned2010-09-06T07:29:06Z-
dc.date.available2010-09-06T07:29:06Z-
dc.date.issued2001en_HK
dc.identifier.citationClinical Cardiology, 2001, v. 24 n. 7, p. 503-505en_HK
dc.identifier.issn0160-9289en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77177-
dc.description.abstractBackground: The role of verapamil in the prevention of atrial fibrillation (AF) in patients with recurrent AF is unknown. Hypothesis: The aim of this study was to evaluate the effect of verapamil on the prevention of AF in patients implanted with an implantable atrial defibrillator (IAD). Methods: The effects of verapamil (240 mg/day) on the total duration of AF, number of AF recurrences, and number of cardioversions were prospectively evaluated in a randomized, crossover fashion over an 8-week period in 11 patients (9 men, 2 women; mean age: 60 ± 6 years) implanted with an IAD. Results: Implantable atrial defibrillators successfully converted 13 of 14 (93%) spontaneous episodes of AF. There was no significant difference in the efficacy of cardioversion (86 vs. 100%, p = 0.8), the total duration of AF (173 ± 198 vs. 270 ± 241 h, p = 0.5), the number of AF episodes (8.5 ± 9.0 vs. 9.3 ± 10.2, p = 0.3), and the number of cardioversions (1.7 ± 2.4 vs. 1.8 ± 2.1, p = 0.7) with or without treatment with verapamil. Conclusions: The results of the present study suggest that treatment with verapamil has no significant effect on the prevention of AF in patients treated with an IAD.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.clinicalcardiology.orgen_HK
dc.relation.ispartofClinical Cardiologyen_HK
dc.subjectAtrial fibrillation-
dc.subjectVerapamil-
dc.subject.meshAnti-Arrhythmia Agents - therapeutic useen_HK
dc.subject.meshAtrial Fibrillation - prevention & controlen_HK
dc.subject.meshCalcium Channel Blockers - therapeutic useen_HK
dc.subject.meshCross-Over Studiesen_HK
dc.subject.meshDefibrillators, Implantableen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshProspective Studiesen_HK
dc.subject.meshRecurrenceen_HK
dc.subject.meshVerapamil - therapeutic useen_HK
dc.titleEffect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillatoren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0160-9289&volume=24&issue=7&spage=503&epage=505&date=2001&atitle=Effect+of+verapamil+on+prevention+of+atrial+fibrillation+in+patients+implanted+with+an+implantable+atrial+defibrillatoren_HK
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/clc.4960240717-
dc.identifier.pmid11450689en_HK
dc.identifier.scopuseid_2-s2.0-0034956327en_HK
dc.identifier.hkuros60549en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034956327&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume24en_HK
dc.identifier.issue7en_HK
dc.identifier.spage503en_HK
dc.identifier.epage505en_HK
dc.identifier.isiWOS:000169516900004-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridWang, Q=7406919551en_HK
dc.identifier.scopusauthoridYu, CM=7404976646en_HK
dc.identifier.scopusauthoridAyers, GM=7102015157en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK
dc.identifier.issnl0160-9289-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats